Evidence map›Paper›PMID 31821323›Full record

ArticlePLoS medicine2019

The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials.

Andrew Vernon, Katherine Fielding, Rada Savic, Lori Dodd, Payam Nahid

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PLoS medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Treatment Strategy for Rifampin-Susceptible Tuberculosis.The New England journal of medicine · 2023
    Trial
  10. Article
  11. Treatment Adherence With an Oral 9-Month Regimen for Rifampicin-Resistant Tuberculosis in South Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Observational
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Andrew VernonClinical Research Branch, Division of TB Elimination, NCHHSTP, US Centers for Disease Control & Prevention, Atlanta, Georgia, United States of America.ORCID 0000-0003-1105-8534
Katherine FieldingTB Centre, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Rada SavicDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, United States of America.
Lori DoddNational Institute for Allergy and Infectious Disease, National Institutes of Health, Washington DC, United States of America.
Payam NahidDivision of Pulmonary and Critical Care Medicine, University of California, San Francisco at San Francisco General Hospital, San Francisco, California, United States of America.ORCID 0000-0003-2811-1311

Funding

Medical Research Council MR/R010161/1
6 · The paper itself

Abstract

Andrew Vernon and co-authors discuss adherence to therapy and its measurement in tuberculosis treatment trials.

Indexed as

Clinical Trials as TopicResearch DesignHumansTuberculosis

Identifiers

PMID31821323
PMCPMC6903706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.